Abstract B091: Preliminary usage of an interactive, clinical trials educational decision aid for Florida cancer patients

Abstract Purpose: CHOICES Decisions Aid (DA) is an evidence-based, interactive, educational decision-making support tool (available in English and Spanish) for patients regarding participation in cancer clinical trials (CCTs). Described here are preliminary data on the first six months following implementation of the CHOICES DA as part of the ACT WONDER2S multi-level intervention aimed at increasing referral and enrollment of diverse patients to CCTs. Methods: CHOICES DA has educational content including facts about CCTs, values clarification exercises on CCT participation, and patient narratives. The site was made accessible via the patient portal to new Moffitt patients residing in seven geographically defined study intervention zones within Moffitt’s catchment area. Eligible patients also received an email with details and a link to the CHOICES DA tool. Patients were offered the option to complete a survey when exiting the site, which included questions about subjective CCT knowledge (range 1-7), preparedness to talk with provider about CCT (range 1-7), CCT decision preparedness (range 1-7), and usefulness and satisfaction with the tool (range 1-10). The mean scores of the survey questions were re-scaled to 100% for comparison. CHOICES DA usage metrics were continuously monitored, including return visits and time spent viewing the site. Results: In the first six months following intervention launch (September 17, 2024 – March 16, 2025), 279 of 1,568 eligible patients (17.8%) visited CHOICES DA. Out of the 279 eligible patients who viewed the site, race demographics were: White 57% (n=159); Black/African American 7.2% (n=20); Other race 6.2% (n=17); Not reported 30% (n=83). Regarding ethnicity, 17% (n=47) were Hispanic/Latino, 51% (n=143) were non-Hispanic/Latino, and 43% (n=89) were unknown ethnicity. The number of users who returned to the site at least once was 23 of 279 (8%), and the number of patients who viewed the Spanish version of the site was 34 of 279 (12%). The mean website viewing time was 5 minutes (range 1-77 minutes), with a mean of 10 page views per patient (range 1-50). A total of 17 (6%) patients completed the survey. Mean self-rated CCT knowledge was 78.6%, readiness to decide about CCTs was 80%, and readiness to discuss CCTs with their doctor was 91.4%. Mean website usefulness and satisfaction were 87% and 86%, respectively. Conclusion: Nearly 1 in 5 eligible patients engaged with CHOICES DA. Early findings suggest CHOICES DA is a relatively low resource approach to reach cancer patients with information about clinical trials. Patients who completed the exit survey gave high ratings to their CCT knowledge and their readiness to discuss and make decisions about participation in a CCT. They also found the site useful. Usage data will be continuously monitored to explore ways to increase adoption. CHOICES DA will later be evaluated at the two-year post-implementation time point, and future analyses will also examine the overall impact on CCTs enrollment and retention, and intervention-specific effects. Citation Format: Elliott Tapia-Kwan, Yayi Zhao, Rossybelle Amorrortu, Lindsay Fuzzell, Melany Garcia, Margaret M. Byrne, Steven Eschrich, Guillermo Gonzalez-Calderon, Dana E. Rollison, Susan T. Vadaparampil. Preliminary usage of an interactive, clinical trials educational decision aid for Florida cancer patients [abstract]. In: Proceedings of the 18th AACR Conference on the Science of Cancer Health Disparities; 2025 Sep 18-21; Baltimore, MD. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2025;34(9 Suppl):Abstract nr B091.